About ACTEMRAACTEMRA was approved by the U.S. Food and Drug...

About ACTEMRA

ACTEMRA was approved by the U.S. Food and Drug Administration (FDA) in January 2010 for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response to one or more tumor necrosis factor (TNF) antagonist therapies.

Patients treated with ACTEMRA are at increased risk for developing serious infections that may lead to hospitalization or death, including tuberculosis (TB), bacterial, invasive fungal, viral, or other opportunistic infections. If a serious infection develops, interrupt ACTEMRA until the infection is controlled.